Merck & Co., Inc. is 213.8x more valuable than UroGen Pharma Ltd. by market capitalization ($293.16 B vs $1.37 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | URGN | MRK |
|---|---|---|
| Market cap | $1.37 B | $293.16 B |
| US-listed rank | #2404 | #44 |
| Revenue (latest FY) | $109.79M | $65.01B |
| Net income (latest FY) | -$153.49M | $18.25B |
| Net margin | -139.8% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 549 | 996 |
Merck & Co., Inc. is 213.8x more valuable than UroGen Pharma Ltd. by market capitalization ($293.16 B vs $1.37 B).
In their latest fiscal years, UroGen Pharma Ltd. reported $109.79M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: UroGen Pharma Ltd. and Merck & Co., Inc., or browse the full rankings.